Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: a Cardiac MRI Study

Running, not enrolling · Has a placebo group

Conditions studied: HIV Infections

In brief

In this study, investigators plan to test whether statins can preserve and/or improve diastolic function among asymptomatic persons with HIV who are on anti-retroviral therapy. Both myocardial fibrosis and myocardial steatosis are thought to contribute to diastolic dysfunction and eventually overt heart failure in HIV. HIV-positive participants will undergo cardiac MRI/MRS imaging studies for the evaluation of myocardial fibrosis and myocardial steatosis prior to initiation of statin or placebo therapy and then two years after initiation of statin or placebo therapy. Traditional markers of cardiovascular (CVD) risk, systemic immune activation/ inflammation, HIV-specific parameters (i.e. CD4 count), and markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS outcomes.

Key facts

Study ID

NCT03238755

Run by

Massachusetts General Hospital

People needed

129

Starts

2017-07-31

Expected to finish

2026-04-23

Last updated by the study team

2024-11-21

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• New enrollment in the REPRIEVE Trial

You may not qualify if…

• clinical diagnosis of HFpEF or HFrEF, by subject report
• standard contraindications to MRI procedure based on MRI Patient Procedure Screening Form - including history of severe allergy to gadolinium

Where it is running

• VA Medical Center-Los Angeles — Los Angeles, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• UTSW Medical Center — Dallas, Texas, United States
• University of Cape Town — Cape Town, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.